THE OUTLOOK FOR THE EVENTUAL CONTROL OF LEUKEMIA

[1] AMANO S, 1952, SEP M INT C HAEM MAR

[2] BEST WR, 1952, J LAB CLIN MED, V40, P778

[3] BIERMAN HR, 1951, CANCER RES, V11, P236

[4] BITTNER JJ, 1946, HARVEY LECT, V42, P221

[5] CLINICAL EVALUATION OF A NEW ANTIMETABOLITE, 6-MERCAPTOPURINE, IN THE TREATMENT OF LEUKEMIA AND ALLIED DISEASES [J]. BLOOD, 1953, 8 (11) : 965 - 999

[6] FOLIC ACID ANTAGONISTS IN THE TREATMENT OF ACUTE AND SUBACUTE LEUKEMIA [J]. BLOOD, 1950, 5 (10) : 898 - 915

[7] DAMESHEK W., 1949, BLOOD JOUR HEMATOL, V4, P338

[8] PHYSIOPATHOLOGY AND COURSE OF POLYCYTHEMIA VERA AS RELATED TO THERAPY [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 142 (11): : 790 - 797

[9] DAMESHEK W, 1950, CHEMOTHERAPY LEUKEMI

[10] DEASUA JT, 1950, REV SOC ARGENT HEMAT, V2, P269

[1] AMANO S, 1952, SEP M INT C HAEM MAR

[2] BEST WR, 1952, J LAB CLIN MED, V40, P778

[3] BIERMAN HR, 1951, CANCER RES, V11, P236

[4] BITTNER JJ, 1946, HARVEY LECT, V42, P221

[5] CLINICAL EVALUATION OF A NEW ANTIMETABOLITE, 6-MERCAPTOPURINE, IN THE TREATMENT OF LEUKEMIA AND ALLIED DISEASES [J]. BLOOD, 1953, 8 (11) : 965 - 999

[6] FOLIC ACID ANTAGONISTS IN THE TREATMENT OF ACUTE AND SUBACUTE LEUKEMIA [J]. BLOOD, 1950, 5 (10) : 898 - 915

[7] DAMESHEK W., 1949, BLOOD JOUR HEMATOL, V4, P338

[8] PHYSIOPATHOLOGY AND COURSE OF POLYCYTHEMIA VERA AS RELATED TO THERAPY [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 142 (11): : 790 - 797

[9] DAMESHEK W, 1950, CHEMOTHERAPY LEUKEMI

[10] DEASUA JT, 1950, REV SOC ARGENT HEMAT, V2, P269